eSense-Lab Ltd. announced that, following receipt of the encouraging research results announced by the company on 27 November 2020, the Company has appointed a Global Chief Executive Officer, Mr. Yoav Elishoov, to drive the company's next stages of growth through commercialisation. Mr. Elishoov's appointment will become effective from 7 December 2020. Concurrent with Mr. Elishoov's appointment, is the resignation of Country CEO, Mr. Itzik Mizrahi, who will depart the company following a three-month transition and handover period between himself and newly appointed Global CEO, Mr. Yoav Elishoov. Mr. Elishoov brings to the company vast experience in commercial, market access, regulatory affairs and marketing roles with global pharmaceutical companies. Mr. Elishoov served as the CEO of Trima Ltd. Under his supervision, Trima Ltd. turned its sales rate to a sustainable growth annually. He positioned the company to become a local generic R&D powerhouse, introducing 4-5 new products annually. In this position and his management of multi-cultural and multidisciplinary teams, Mr. Elishoov developed strong and close communication with decision-makers in the pharmaceuticals business, regulatory authorities, reimbursement regulators, HMOs, hospitals, key opinion leaders and pharmacies.